rs151344614
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_ModerateBP7BS2_Supporting
The NM_001142459.2(ASB10):c.1092G>T(p.Gly364Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000214 in 1,543,872 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as not provided (no stars).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000021 ( 0 hom. )
Consequence
ASB10
NM_001142459.2 synonymous
NM_001142459.2 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.150
Publications
0 publications found
Genes affected
ASB10 (HGNC:17185): (ankyrin repeat and SOCS box containing 10) The protein encoded by this gene is a member of the ankyrin repeat and SOCS box-containing (ASB) family of proteins. The SOCS box serves to couple suppressor of cytokine signaling (SOCS) proteins and their binding partners with the elongin B and C complex, possibly targeting them for degradation. Multiple alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Dec 2008]
ASB10 Gene-Disease associations (from GenCC):
- glaucoma 1, open angle, FInheritance: AD, Unknown Classification: LIMITED Submitted by: ClinGen, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -4 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.45).
BP7
Synonymous conserved (PhyloP=0.15 with no splicing effect.
BS2
High AC in GnomAdExome4 at 29 AD,Unknown gene. Variant has AC lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ASB10 | NM_001142459.2 | c.1092G>T | p.Gly364Gly | synonymous_variant | Exon 3 of 6 | ENST00000420175.3 | NP_001135931.2 | |
| ASB10 | NM_080871.4 | c.1047G>T | p.Gly349Gly | synonymous_variant | Exon 3 of 6 | NP_543147.2 | ||
| ASB10 | NM_001142460.1 | c.1092G>T | p.Gly364Gly | synonymous_variant | Exon 3 of 5 | NP_001135932.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| ASB10 | ENST00000420175.3 | c.1092G>T | p.Gly364Gly | synonymous_variant | Exon 3 of 6 | 1 | NM_001142459.2 | ENSP00000391137.2 | ||
| ASB10 | ENST00000275838.5 | c.1092G>T | p.Gly364Gly | synonymous_variant | Exon 3 of 5 | 1 | ENSP00000275838.1 | |||
| ASB10 | ENST00000377867.7 | c.1047G>T | p.Gly349Gly | synonymous_variant | Exon 3 of 6 | 2 | ENSP00000367098.3 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152240Hom.: 0 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
4
AN:
152240
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.0000629 AC: 12AN: 190902 AF XY: 0.0000952 show subpopulations
GnomAD2 exomes
AF:
AC:
12
AN:
190902
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000208 AC: 29AN: 1391514Hom.: 0 Cov.: 31 AF XY: 0.0000322 AC XY: 22AN XY: 682986 show subpopulations
GnomAD4 exome
AF:
AC:
29
AN:
1391514
Hom.:
Cov.:
31
AF XY:
AC XY:
22
AN XY:
682986
show subpopulations
African (AFR)
AF:
AC:
0
AN:
31954
American (AMR)
AF:
AC:
0
AN:
37898
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
22718
East Asian (EAS)
AF:
AC:
0
AN:
38270
South Asian (SAS)
AF:
AC:
8
AN:
78428
European-Finnish (FIN)
AF:
AC:
0
AN:
47896
Middle Eastern (MID)
AF:
AC:
2
AN:
4362
European-Non Finnish (NFE)
AF:
AC:
17
AN:
1072840
Other (OTH)
AF:
AC:
2
AN:
57148
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.491
Heterozygous variant carriers
0
3
6
8
11
14
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152358Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74508 show subpopulations
GnomAD4 genome
AF:
AC:
4
AN:
152358
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74508
show subpopulations
African (AFR)
AF:
AC:
0
AN:
41582
American (AMR)
AF:
AC:
0
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3468
East Asian (EAS)
AF:
AC:
0
AN:
5182
South Asian (SAS)
AF:
AC:
0
AN:
4828
European-Finnish (FIN)
AF:
AC:
0
AN:
10630
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
4
AN:
68042
Other (OTH)
AF:
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.563
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: not provided
Submissions summary: Other:1
Revision: no classification provided
LINK: link
Submissions by phenotype
Glaucoma 1, open angle, F Other:1
-
Casey Eye Institute Glaucoma Genetics Lab
Significance:not provided
Review Status:no classification provided
Collection Method:literature only
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.